Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Dermata Therapeutics Inc (DRMA)

Dermata Therapeutics Inc (DRMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,265
  • Shares Outstanding, K 6,661
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,790 K
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.21
Trade DRMA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.65
  • Most Recent Earnings $-0.21 on 03/21/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.92
  • Growth Rate Est. (year over year) +52,131.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2320 +47.72%
on 04/16/24
0.4444 -22.88%
on 04/04/24
-0.0613 (-15.17%)
since 03/26/24
3-Month
0.2320 +47.72%
on 04/16/24
0.5770 -40.61%
on 01/30/24
-0.1769 (-34.05%)
since 01/26/24
52-Week
0.2320 +47.72%
on 04/16/24
3.6800 -90.69%
on 05/12/23
-1.5173 (-81.58%)
since 04/26/23

Most Recent Stories

More News
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

CRSP : 53.91 (+0.34%)
KALA : 6.30 (+1.94%)
ALLO : 2.89 (+1.23%)
DRMA : 0.3427 (+0.76%)
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea

- Topline results expected in the second half of 2022 -

DRMA : 0.3427 (+0.76%)
Dermata to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 0.3427 (+0.76%)
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA;...

DRMA : 0.3427 (+0.76%)
DRMAW : 0.0095 (+3.26%)
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of...

DRMA : 0.3427 (+0.76%)
DRMAW : 0.0095 (+3.26%)
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment...

DRMA : 0.3427 (+0.76%)
DRMAW : 0.0095 (+3.26%)
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase...

DRMA : 0.3427 (+0.76%)
DRMAW : 0.0095 (+3.26%)
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 0.3427 (+0.76%)
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic...

DRMA : 0.3427 (+0.76%)
Dermata to Present at the H.C. Wainwright BioConnect Conference

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 0.3427 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

See More

Key Turning Points

3rd Resistance Point 0.3823
2nd Resistance Point 0.3703
1st Resistance Point 0.3565
Last Price 0.3427
1st Support Level 0.3307
2nd Support Level 0.3187
3rd Support Level 0.3049

See More

52-Week High 3.6800
Fibonacci 61.8% 2.3629
Fibonacci 50% 1.9560
Fibonacci 38.2% 1.5491
Last Price 0.3427
52-Week Low 0.2320

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar